
ARNA
Healthcare · Biotechnology · $6.17B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2022
EPS trend, 90 days to now · -4.2% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 23, 2022 | After the close | -2.26 | -2.39 | -5.8% |
| Nov 4, 2021 | After the close | -2.52 | -3.21 | -27.4% |
| Aug 5, 2021 | After the close | -2.17 | -2.40 | -10.5% |
| May 5, 2021 | After the close | -2.22 | -1.98 | +10.8% |
| Feb 23, 2021 | After the close | -1.81 | -2.10 | -16.2% |
| Nov 9, 2020 | After the close | -1.86 | -1.69 | +9.0% |
| Aug 5, 2020 | After the close | -2.00 | -1.61 | +19.7% |
| May 7, 2020 | After the close | -2.42 | -2.00 | +17.3% |
| Feb 26, 2020 | After the close | -1.54 | -1.76 | -14.2% |
| Nov 7, 2019 | After the close | -1.31 | -1.46 | -11.5% |
| Aug 7, 2019 | After the close | -1.07 | -1.24 | -15.5% |
| May 8, 2019 | After the close | 14.31 | 12.10 | -15.4% |
| Feb 26, 2019 | After the close | -0.73 |
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for…
| 1.35 |
| +285.0% |
| Nov 7, 2018 | After the close | -0.74 | -0.70 | +5.1% |
| Aug 6, 2018 | After the close | -0.64 | -0.65 | -1.8% |
| May 8, 2018 | After the close | -0.64 | -0.78 | -21.3% |
| Mar 14, 2018 | After the close | -0.57 | -0.35 | +39.2% |